Helus Pharma Completes Enrollment In Its APPROACH Phase 3 Study Of HLP003 In Patients Living With Major Depressive Disorder; Topline Data Readout On Track For Q4 2026
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dataHLP003 previously
Helus Pharma finished signing up patients for a big test of a new depression medicine called HLP003. This is a good checkpoint, and the company expects to share results at the end of 2026—watch if they deliver on that promise and if the results look strong.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.